Apredica Acquired by Cyprotex

August 6, 2010

Apredica announces that it was acquired by Cyprotex. See press release. Katya Tsaion, Ph.d., Apredica's CEO, and Doug Bates, Apredica's Chief Business Officer, will be joining the Cyprotex Board of Directors.

Apredica Acquires Cellumen Assets

August 4, 2010

Apredica announces that the assets of Cellumen Inc. were acquired by Apredica on August 4, 2010.

The acquisition of the Cellumen assets gives Apredica the intellectual property for offering the Cellular Systems Biology (CSB™) and High Content Toxicology services developed and commercialized by Cellumen, Inc. Apredica will be adding these to its existing High Content Toxicology offering, and is committed to both the continued commercialization and the expansion of this technology in the years to come to other biological models, such as additional primary-cell and stem cell-derived models.

The former owners of the Cellumen assets, who continue to own the company formerly known as Cellumen, Inc., have closed Cellumen's Pittsburgh facility. We are in the process of relocating Cellumen's equipment and intellectual property to Apredica's Watertown, MA facility. Five former Cellumen Inc. employees are working with Apredica through the transition and may stay on as Apredica employees.

Full provision of the Cellumen services formerly provided in Pittsburgh will resume by September at our Watertown laboratory.

Contact us to learn more about Apredica's acquisition of the Cellumen assets.